Med7 LLC, announce the completion of a security and efficacy examine utilizing Hempzorb81TM Full Spectrum Hemp Oil in sufferers with Kind II Diabetes

0
358

Hempzorb81TM showed a significant effect in reducing A1c with an average decrease of 1.2 points … over six months.

Tweet this

Cannabidiol (CBD) alone or in combination with other cannabinoids has never shown a proven clinical effect on glucose management in large placebo-controlled studies. “A naturally occurring whole plant extract with multiple cannabinoids and other natural constituents can have powerful effects on cannabinoid receptors if they can get into the bloodstream effectively,” she said Paul Murray, CEO of HempCo. “These studies should give consumers and suppliers the confidence that there are hemp products that contain CBD and are based on human clinical studies.”

Med7 also received support from the NIH with two other studies: The effect of Hempzorb81TM on sleep cycles and in patients with COVID-19. “The study in COVID-19 patients was a coincidence for our diabetes study and the pandemic. In the first few months of this clinical trial, COVID-19 hit the study group hard,” said Smith. “None of the subjects with COVID-19 stopped the study or were hospitalized, so we examined these patients more closely. We are evaluating these results and hope to release them soon.”

About Med7

Med7® is a technology-driven health and wellness company selling full-spectrum hemp CBD oil products with Purzorb® to medical professionals. Purzorb® is a patent-pending technology that mimics the body’s natural absorption process by converting oil-based nutrients into water-soluble products.

SOURCE Med7

similar links

http://www.Med7cbd.com